{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:59:09Z","timestamp":1787594349201,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ottawa Hospital Academic Medical Organization"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Granulocyte colony-stimulating factors (G-CSFs), including filgrastim and pegfilgrastim, are associated with bone pain, potentially impacting treatment adherence. This study hypothesized that a 5-day regimen of filgrastim would result in less bone pain than single-dose pegfilgrastim in patients receiving chemotherapy for early breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this multicenter, open-label, randomized controlled trial, patients requiring prophylactic G-CSF during chemotherapy were randomly assigned 1:1 to receive either 5-day filgrastim or pegfilgrastim. The primary outcome was patient-reported bone pain, assessed as area under the curve of daily pain scores (0\u2009=\u2009no pain to 10\u2009=\u2009worst pain) over the first 5\u2009days following G-CSF in cycle 1. Secondary outcomes included bone pain in cycles 2-4, febrile neutropenia, hospitalizations, chemotherapy delays, dose reductions, early discontinuations, chemotherapy-related deaths, health-related quality of life, and health-care resource utilization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From June 2021 to March 2023, a total of 233 patients were randomly assigned, with 219 analyzed (110 filgrastim and 109 pegfilgrastim) after excluding those who withdrew before receiving treatment. Adjusting for stratification factors and prespecified baseline covariates using repeated measures linear regression, the mean area under the curve (0-40) for cycle 1 bone pain was 10.2 (11.2) for 5-day filgrastim and 10.2 (9.81) for pegfilgrastim, with an adjusted mean difference of 0.70 (95% confidence interval = 1.62 to 3.02; P\u2009=\u2009.556). Although no clinically significant differences were observed in most secondary outcomes, the 5-day filgrastim group exhibited a numerically higher incidence of febrile neutropenia (6.4% vs 0.9%, P\u2009=\u2009.065) and hospitalization (10.0% vs 3.7%, P\u2009=\u2009.106).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There was no significant difference in bone pain between 5-day filgrastim and pegfilgrastim.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkaf081","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T11:40:28Z","timestamp":1754739628000},"source":"Crossref","is-referenced-by-count":2,"title":["REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6128-3137","authenticated-orcid":false,"given":"Terry L","family":"Ng","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Ottawa , Ottawa, ON,","place":["Canada"]},{"name":"Cancer Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]},{"name":"The Ottawa Hospital Cancer Centre , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4997-8742","authenticated-orcid":false,"given":"Peter","family":"Greenstreet","sequence":"additional","affiliation":[{"name":"Ottawa Methods Centre, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Stober","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0485-9069","authenticated-orcid":false,"given":"Stuart","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Methodological and Implementation Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]},{"name":"Office for Patient Engagement in Research Activity, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7196-8998","authenticated-orcid":false,"given":"Jennifer","family":"Shamess","sequence":"additional","affiliation":[{"name":"Champlain Regional Cancer Care Patient and Family Advisory Council , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Mills","sequence":"additional","affiliation":[{"name":"St Joseph Family Medical Clinic , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2842-6110","authenticated-orcid":false,"given":"Mohammed","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Northern Ontario School of Medicine University , Thunder Bay, ON,","place":["Canada"]},{"name":"Thunder Bay Regional Health Sciences Centre , Thunder Bay, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-0870","authenticated-orcid":false,"given":"Marie-France","family":"Savard","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Ottawa , Ottawa, ON,","place":["Canada"]},{"name":"Cancer Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]},{"name":"The Ottawa Hospital Cancer Centre , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Rushton","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Ottawa , Ottawa, ON,","place":["Canada"]},{"name":"Cancer Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]},{"name":"The Ottawa Hospital Cancer Centre , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8552-6831","authenticated-orcid":false,"given":"Arif","family":"Awan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Ottawa , Ottawa, ON,","place":["Canada"]},{"name":"Cancer Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]},{"name":"The Ottawa Hospital Cancer Centre , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-2263","authenticated-orcid":false,"given":"Sandeep","family":"Sehdev","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Ottawa , Ottawa, ON,","place":["Canada"]},{"name":"Cancer Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]},{"name":"The Ottawa Hospital Cancer Centre , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hilton","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Ottawa , Ottawa, ON,","place":["Canada"]},{"name":"Cancer Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]},{"name":"The Ottawa Hospital Cancer Centre , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinni","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Ottawa , Ottawa, ON,","place":["Canada"]},{"name":"Cancer Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]},{"name":"The Ottawa Hospital Cancer Centre , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-2009","authenticated-orcid":false,"given":"Parvaneh","family":"Fallah","sequence":"additional","affiliation":[{"name":"Gerald Bronfman Department of Oncology, McGill University , Montreal, Quebec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Ottawa , Ottawa, ON,","place":["Canada"]},{"name":"Department of Medicine, King Abdulaziz Hospital , Alhasa,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0039-0782","authenticated-orcid":false,"given":"Daniel","family":"Davoudpour","sequence":"additional","affiliation":[{"name":"Thunder Bay Regional Health Sciences Centre , Thunder Bay, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Daigle","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"MacDonald","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5921-1441","authenticated-orcid":false,"given":"Lisa","family":"Vandermeer","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3978-8961","authenticated-orcid":false,"given":"Monica","family":"Taljaard","sequence":"additional","affiliation":[{"name":"Ottawa Methods Centre, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]},{"name":"Methodological and Implementation Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9392-8219","authenticated-orcid":false,"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Ottawa , Ottawa, ON,","place":["Canada"]},{"name":"Cancer Research Program, Ottawa Hospital Research Institute , Ottawa, ON,","place":["Canada"]},{"name":"The Ottawa Hospital Cancer Centre , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2025092618570936400_pkaf081-B1","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.1995.13.7.1564","article-title":"Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer","volume":"13","author":"Chevallier","year":"1995","journal-title":"J Clin Oncol"},{"key":"2025092618570936400_pkaf081-B2","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1200\/JCO.1996.14.11.2976","article-title":"Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer","volume":"14","author":"Jones","year":"1996","journal-title":"J Clin Oncol"},{"key":"2025092618570936400_pkaf081-B3","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025092618570936400_pkaf081-B4","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025092618570936400_pkaf081-B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J Natl Compr Cancer Netw"},{"key":"2025092618570936400_pkaf081-B6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"2025092618570936400_pkaf081-B7","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"2025092618570936400_pkaf081-B8","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","article-title":"Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer","volume":"13","author":"Holmes","year":"2002","journal-title":"Ann Oncol"},{"key":"2025092618570936400_pkaf081-B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"key":"2025092618570936400_pkaf081-B10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"key":"2025092618570936400_pkaf081-B11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3816\/cbc.2003.n.003","article-title":"Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer","volume":"3","author":"Kubista","year":"2003","journal-title":"Clin Breast Cancer"},{"key":"2025092618570936400_pkaf081-B12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.annonc.2020.04.005","article-title":"A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer","volume":"31","author":"Clemons","year":"2020","journal-title":"Annals of Oncology"},{"key":"2025092618570936400_pkaf081-B13","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00520-018-4074-8","article-title":"Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients","volume":"26","author":"Hilton","year":"2018","journal-title":"Support Care Cancer"},{"key":"2025092618570936400_pkaf081-B14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025092618570936400_pkaf081-B15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol"},{"key":"2025092618570936400_pkaf081-B16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamaoncol.2019.5566","article-title":"Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials","volume":"6","author":"Atkinson","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025092618570936400_pkaf081-B17","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/NCC.0b013e318269040f","article-title":"Comparison between patient-reported and clinician-observed symptoms in oncology","volume":"36","author":"Xiao","year":"2013","journal-title":"Cancer Nurs"},{"key":"2025092618570936400_pkaf081-B18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1548-5315(11)70107-3","article-title":"Pegfilgrastim-induced bone pain: incidence, risk factors, and management in a community practice","volume":"4","author":"Kirshner","year":"2007","journal-title":"Community Oncology"},{"key":"2025092618570936400_pkaf081-B19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/biology11020340","article-title":"Comparative study of adverse drug reactions associated with Filgrastim and Pegfilgrastim using the EudraVigilance database","volume":"11","author":"Rastogi","year":"2022","journal-title":"Biology"},{"key":"2025092618570936400_pkaf081-B20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10549-019-05274-0","article-title":"Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT)","volume":"177","author":"Basulaiman","year":"2019","journal-title":"Breast Cancer Res Treat. Published"},{"key":"2025092618570936400_pkaf081-B21","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2011.37.8364","article-title":"Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base","volume":"30","author":"Kirshner","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025092618570936400_pkaf081-B22","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"2025092618570936400_pkaf081-B23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/s0197-2456(00)00061-1","article-title":"How to select covariates to include in the analysis of a clinical trial","volume":"21","author":"Raab","year":"2000","journal-title":"Control Clin Trials"},{"key":"2025092618570936400_pkaf081-B24","author":"U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)","year":"2024"},{"key":"2025092618570936400_pkaf081-B25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1745-6215-15-139","article-title":"The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies","volume":"15","author":"Kahan","year":"2014","journal-title":"Trials"},{"key":"2025092618570936400_pkaf081-B26","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jclinepi.2003.09.014","article-title":"Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements","volume":"57","author":"Hern\u00e1ndez","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2025092618570936400_pkaf081-B27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000011926","article-title":"Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide","volume":"56","author":"Koumakis","year":"1999","journal-title":"Oncology"},{"key":"2025092618570936400_pkaf081-B28","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00520-015-2941-0","article-title":"Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review","volume":"24","author":"Fernandes","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025092618570936400_pkaf081-B29","author":"Formulary Search\u2014Search Results","year":"2025"},{"key":"2025092618570936400_pkaf081-B30","author":"Formulary Search\u2014Search Results","year":"2025"},{"key":"2025092618570936400_pkaf081-B31","author":"Ottawa Hospital Research Institute","year":"2025"},{"key":"2025092618570936400_pkaf081-B32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.breast.2021.03.012","article-title":"A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia","volume":"58","author":"Clemons","year":"2021","journal-title":"Breast"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaf081\/64046292\/pkaf081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/5\/pkaf081\/64046292\/pkaf081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/5\/pkaf081\/64046292\/pkaf081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T22:57:13Z","timestamp":1758927433000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaf081\/8234546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaf081","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,14]]},"article-number":"pkaf081"}}